share_log

Tilray Remains a Solid Pot Play

Tilray Remains a Solid Pot Play

Tilray仍然是一个可靠的博彩游戏
InvestorPlace ·  2021/11/22 15:16

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

InvestorPlace-股市新闻、股票咨询和交易提示

Tilray (NASDAQ:TLRY) stock has climbed since October, but it remains far below its past highs. After the Democratic Party's "blue wave" in last year's U.S. elections failed to result in  legalization, the retreat of Canada-based cannabis plays like TLRY stock makes sense.

Tilray(纳斯达克:TLRY)股价自去年10月以来一直在攀升,但仍远低于过去的高点。在民主党在去年美国大选中的“蓝色浪潮”未能导致大麻合法化后,加拿大大麻的撤退就像TLRY股票一样有意义。

Pot is now legal in dozens of U.S. states. But without changes in federal law, Canadian names like Tilray  can't enter  the U.S., which could become the  world's largest legal cannabis market. Before diving back into Tilray, Canopy Growth (NASDAQ:CGC), and others, investors are waiting for Congress to legalize marijuana.

大麻现在美国几十个州都是合法的。但如果不修改联邦法律,像Tilray这样的加拿大名字就不能进入美国,美国可能成为世界上最大的合法大麻市场。在潜入Tilray之前,冠层生长纳斯达克(Sequoia Capital:CGC)和其他公司的投资者正在等待国会将大麻合法化。

Consequently, TLRY stock and its peers could continue to deliver mediocre returns in the near-term. Yet this "out of favor" status for the sector among Main Street and Wall Street investors may provide investors with a good opportunity. Despite doubts about whether U.S. legalization will ever occur, there's a good chance that the drug will be legalized in a few short years.

因此,TLRY股票及其同行可能在短期内继续提供平庸的回报。然而,该行业在普通民众和华尔街投资者中的这种“失宠”状态可能会为投资者提供一个很好的机会。尽管对美国是否会合法化存在疑问,但这种药物很有可能在短短几年内合法化。

Further, Tilray has some other possible, positive catalysts on the table. Although the shares may not rally for some time, you may want to take a bullish position in the name, since its share price is likely to undergo  an epic rebound.

此外,Tilray还有其他一些可能的、积极的催化剂摆在桌面上。虽然股价可能在一段时间内不会反弹,但你可能希望在名义上持看涨立场,因为它的股价很可能经历Epic的反弹。

Recent Pot Legalization News

最近的大麻合法化新闻

Oddly enough, the most recent push for reform has come not from the Democrats, but from a Republican.

奇怪的是,最近推动改革的不是民主党人,而是共和党人。

On Nov 16, Rep. Nancy Mace (R-SC) introduced a marijuana decriminalization bill. The bill would eliminate all  federal restrictions on the drug. At the same time, it would enable states to decide whether to legalize it.

11月16日,众议员南希·梅斯(R-SC)提出了一项大麻非刑事化法案。该法案将取消联邦政府对该药物的所有限制。与此同时,它将使各州能够决定是否将其合法化。

This bill alone doesn't signal that the Republicans are about to become as pro-pot as the Democrats. After all, the Republican Party in Mace's home state of South Carolina has expressed its opposition to her bill. But Mace's bill bolsters the argument that legalization is becoming more of a bipartisan issue. So no matter which party controls Congress after the 2022 midterm elections, marijuana reform is still just around the corner.

仅凭这项法案并不能表明共和党人即将变得像民主党人一样支持大麻。毕竟,梅斯的家乡南卡罗来纳州的共和党已经表达了对她的法案的反对。但梅斯的法案支持了合法化越来越成为两党问题的论点。因此,无论哪个政党在2022年中期选举后控制国会,大麻改革仍指日可待。

  • 7 Stocks to Watch Now as Consumer Prices Spike

  • 消费者价格飙升,现在值得关注的7只股票

As  Tilray CEO Irwin Simon has said, legalization is far from a silver bullet when it comes to solving this company's problems. Even if Congress legalizes the drug soon, Tilray's financial results would not improve  tremendously for some time.

正如Tilray首席执行官欧文·西蒙所说,要解决这家公司的问题,合法化远非灵丹妙药。即使国会很快将该药物合法化,Tilray的财务业绩在一段时间内也不会有太大改善。

That said, progress towards legalization would cause a spike in its stock price. After the electric vehicle (EV) and related stocks went up following Congress' passing of the infrastructure bill, popular pot stocks could embark on a similar rally if lawmakers  moves towards legalizing the drug.

也就是说,合法化的进展将导致其股价飙升。在国会通过基础设施法案后,电动汽车(EV)和相关股票上涨后,如果立法者朝着毒品合法化迈进,受欢迎的大麻类股可能会出现类似的涨势。

Other Possible Catalysts Could Lift the Shares

其他可能的催化剂可能会提振股价

Tilray's  potential gains from pot reform may outweigh its possible drops. But among the Canada-based cannabis stocks, names like Sundial Growers (NASDAQ:SNDL) may be better ways to wager on this catalyst. With Sundial's low stock price, it could spike more dramatically than Tilray on progress towards  U.S. legalization.

Tilray从大麻改革中获得的潜在收益可能会超过其可能的跌幅。但在加拿大的大麻库存中,像这样的名字日规种植者纳斯达克(Sequoia Capital:SNDL)可能是押注于这一催化剂的更好方式。由于Sunial的股价较低,在美国合法化的进展方面,它可能会比Tilray更戏剧性地飙升。

However, there's more on Tilray's side than just the prospect of it entering the American pot market within a few years. Other catalysts could help  its stock price rebound.

然而,Tilray的方面不仅仅是它在几年内进入美国大麻市场的前景。其他催化剂可能有助于其股价反弹。

I discussed two of these catalysts when I last wrote about TLRY stock last month. First, the company plans to grow its share of the high-margin medical pot market in Canada and Europe. Second,  its strategy to buy  other pot companies could enable it to save money.

上个月我在写关于TLRY股票的文章时讨论了其中的两个催化剂。首先,该公司计划扩大其在加拿大和欧洲高利润率医用大麻市场的份额。其次,它收购其他大麻公司的战略可以让它省钱。

On top of this, the company could grow its exposure to the U.S. pot market while reforms are pending. It could do so  by making more deals similar  to the one it concluded with MedMen Enterprises (OTCMKTS:MMNFF) earlier this year. This complex transaction, which involved the use of convertible securities and warrants, gave it an economic interest in the U.S.-based pot purveyor.

最重要的是,在改革悬而未决的同时,该公司可能会增加对美国大麻市场的敞口。它可以通过达成更多类似于它与之达成的交易来做到这一点。梅德曼企业(OTCMKTS:MMNFF)今年早些时候。这笔复杂的交易涉及使用可转换证券和认股权证,使其在这家美国大麻供应商中获得了经济利益。

The Bottom Line on TLRY Stock

TLRY股票的底线

It's understandable why Tilray and its peers are still out of favor. But that doesn't mean that the name will continue to underwhelm investors. The shares could spike on any legalization news. Or other parts of its game plan could become successful, enabling its share price to start rebounding.

Tilray和它的同行仍然失宠,这是可以理解的。但这并不意味着这个名字将继续让投资者印象不佳。任何合法化消息都可能导致该公司股价飙升。或者,它的游戏计划的其他部分可能会变得成功,使其股价开始反弹。

With TLRY stock already beaten down, a shift in investors' sentiment could enable it to pop tremendously  down the road. Before that happens,  bottom fishers may want to buy it.

由于TLRY的股票已经受到重创,投资者情绪的转变可能会使它在未来大幅上涨。在此之前,底层捕鱼者可能会想买下它。

On the date of publication, Thomas Niel did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

在出版之日,托马斯·尼尔没有(直接或间接)持有本文所述证券的任何头寸。本文中表达的观点是作者的观点,受InvestorPlace.com发布指南的约束。

Thomas Niel, a contributor for InvestorPlace.com, has been writing single-stock analysis for web-based publications since 2016.

托马斯·尼尔(Thomas Niel),InvestorPlace.com,自2016年以来一直在为基于网络的出版物撰写单一股票分析。

The post Tilray Remains a Solid Pot Play appeared first on InvestorPlace.

帖子Tilray仍然是一个坚实的Pot Play最先出现在InvestorPlace上。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发